îæ€çŽ¢
îæ€çŽ¢
î
Neurosense Therapeutics Ltd
NRSNîãŠã©ãããªã¹ãã«è¿œå
0.723USD
+0.003+0.42%
çµå€Â 07/01, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
23.54Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现ãã£ãŒãã衚瀺
TradingKey åŸè¡šIntraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+0.42%
5æ¥é
-5.83%
1ã¶æ
-11.98%
6ã¶æ
-5.98%
幎åæ¥
-5.98%
1幎é
-61.75%
äž»èŠããŒã¿
0.720å§å€
0.740é«å€
91.26Kåºæ¥é«
æ倱é¡çŽè¿12ã¶æPER
æ倱é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
0.37%売買å転ç
0.720åæ¥çµå€
0.710å®å€
40.98K売買代é
æ倱é¡æ ªäŸ¡åçç
-15.00PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-397.11%ç·è³ç£å©çç
2.19052é±é«å€
0.75åºæ¥é«æ¯ç%
-10.21MçŽå©ç
32.56Mæ ªåŒæ°
-0.43661æ ªåœããå©çïŒEPSïŒ
1.57ããŒã¿å€
-2174.98%èªå·±è³æ¬å©çç
0.63052é±å®å€
4.79%æ¯ãå¹
--ç²å©çç
23.54Mæ䟡ç·é¡
-2.40ãªã¹ã¯ãªã¿ãŒã³
5.64%ãªã¹ã¯ç
TradingKey æ ªåŒã¹ã³ã¢
ããŒã¿ãäžååãªãããæ ªåŒã¹ã³ã¢ã¯å©çšã§ããŸããã
Neurosense Therapeutics Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Neurosense Therapeutics Ltdã®äŒæ¥æ å ±î
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
äŒæ¥ã³ãŒãNRSN
äŒæ¥åNeurosense Therapeutics Ltd
æé«çµå¶è²¬ä»»è
ãCEOãBen-Noon (Alon)
ãŠã§ããµã€ãhttps://www.neurosense-tx.com/
é¢é£éèåå
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%人æ°éæ
52265.700
+11.400Â (+0.02%)
29847.900
+48.600Â (+0.16%)
7482.400
+6.900Â (+0.09%)
15354.000
-1.000Â (-0.01%)
69649.000
+164.000Â (+0.24%)
6279.600
+4.200Â (+0.07%)
67.944
-0.024Â (-0.04%)
294.380
+5.020Â (+1.73%)
197.580
-2.510Â (-1.25%)
4038.000
+7.230Â (+0.18%)
ãããã質å
Neurosense Therapeutics LtdïŒNRSNïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îNeurosense Therapeutics LtdïŒNRSNïŒã®çŸåšã®æ ªäŸ¡ã¯0.72ã§ãã
Neurosense Therapeutics Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îNeurosense Therapeutics Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯NRSNã§ãã
Neurosense Therapeutics Ltdã®52é±é«å€ã¯ãããã§ããïŒ
îNeurosense Therapeutics Ltdã®52é±é«å€ã¯2.19ã§ãã
Neurosense Therapeutics Ltdã®52é±å®å€ã¯ãããã§ããïŒ
îNeurosense Therapeutics Ltdã®52é±å®å€ã¯0.63ã§ãã
Neurosense Therapeutics Ltdã®æ䟡ç·é¡ã¯ãããã§ããïŒ
îNeurosense Therapeutics Ltdã®æ䟡ç·é¡ã¯25.45Mã§ãã
Neurosense Therapeutics Ltd (NRSN) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãNeurosense Therapeutics LtdïŒNRSNïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯6.50ã§ãã
Neurosense Therapeutics Ltd (NRSN) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îNeurosense Therapeutics LtdïŒNRSNïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.44ã§ãã